These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36864544)

  • 1. Commercial health plans use of patient subgroup restrictions: An analysis of orphan and US Food and Drug Administration-expedited programs.
    Jenkins NB; Rucker JA; Klimchak AC; Sedita LE; Chambers JD
    J Manag Care Spec Pharm; 2023 May; 29(5):472-479. PubMed ID: 36864544
    [No Abstract]   [Full Text] [Related]  

  • 2. The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverage.
    Panzer AD; Ingham M; Martin S; Chambers JD
    J Manag Care Spec Pharm; 2023 May; 29(5):464-471. PubMed ID: 36989444
    [No Abstract]   [Full Text] [Related]  

  • 3. Specialty drug coverage varies between health plans' medical and pharmacy benefit policies.
    Levine AA; Panzer AD; Kauf TL; O'Sullivan AK; Strand L; Chambers JD
    J Manag Care Spec Pharm; 2023 Jun; 29(6):607-613. PubMed ID: 37276044
    [No Abstract]   [Full Text] [Related]  

  • 4. Variation in health plan coverage of ESAs for anemia due to chronic kidney disease.
    Margaretos NM; Panzer AD; Lai RC; Sanon M; Michalopoulos E; Redmond AM; Moghadam R; Chambers JD
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1221-1229. PubMed ID: 34464213
    [No Abstract]   [Full Text] [Related]  

  • 5. US commercial health plan coverage dynamics in pulmonary arterial hypertension therapies.
    Rucker JA; Beinfeld MT; Enright DE; Germack HD; Panjabi S; Chakinala MM; Chambers JD
    J Manag Care Spec Pharm; 2024 Jun; 30(6):541-548. PubMed ID: 38824632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients' access to 2018 FDA-approved drugs 1 year post approval.
    Panzer AD; Margaretos NM; Bridger N; Osani MC; Lai RC; Chambers JD
    Am J Manag Care; 2022 Apr; 28(4):e153-e156. PubMed ID: 35420754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commercial coverage of specialty drugs, 2017-2021.
    Rucker JA; Beinfeld MT; Jenkins NB; Enright DE; Henderson RR; Chambers JD
    Health Aff Sch; 2023 Aug; 1(2):qxad030. PubMed ID: 38756241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of prescriber requirements among US commercial health plans.
    Lenahan K; Panzer AD; Gertler R; Chambers JD
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1757-1762. PubMed ID: 34818091
    [No Abstract]   [Full Text] [Related]  

  • 9. Is an Orphan Drug's Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?
    Chambers JD; Margaretos NM; Enright DE; Wang R; Ye X
    Pharmacoeconomics; 2022 Feb; 40(2):225-232. PubMed ID: 34697718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
    Shaw DL; Dhruva SS; Ross JS
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examining US commercial health plans' use of The Institute for Clinical and Economic Review's reports in specialty drug coverage decisions.
    Chambers JD; Enright DE; Panzer AD; Cohen JT; Ollendorf DA; Neumann PJ
    J Manag Care Spec Pharm; 2023 Mar; 29(3):257-264. PubMed ID: 36840954
    [No Abstract]   [Full Text] [Related]  

  • 12. Variation in Private Payer Coverage of Rheumatoid Arthritis Drugs.
    Chambers JD; Wilkinson CL; Anderson JE; Chenoweth MD
    J Manag Care Spec Pharm; 2016 Oct; 22(10):1176-81. PubMed ID: 27668566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients' access to rare neuromuscular disease therapies varies across US private insurers.
    Margaretos NM; Bawa K; Engmann NJ; Chambers JD
    Orphanet J Rare Dis; 2022 Feb; 17(1):36. PubMed ID: 35123543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation in access to hemophilia A treatments in the United States.
    Margaretos NM; Patel AM; Panzer AD; Lai RC; Whiteley J; Chambers JD
    J Med Econ; 2021; 24(1):1143-1148. PubMed ID: 34538215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies.
    Chambers JD; Pope EF; Wilkinson CL; Neumann PJ
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1240-1246. PubMed ID: 30479201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variation in US private health plans' coverage of orphan drugs.
    Chambers JD; Panzer AD; Kim DD; Margaretos NM; Neumann PJ
    Am J Manag Care; 2019 Oct; 25(10):508-512. PubMed ID: 31622066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Varied use of step therapy among Medicare Advantage plans.
    Jenkins NB; Nichols DE; Enright DE; Chambers JD
    Am J Manag Care; 2023 Sep; 29(9):464-468. PubMed ID: 37729529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coverage of New Drugs in Medicare Part D.
    Naci H; Kyriopoulos I; Feldman WB; Hwang TJ; Kesselheim AS; Chandra A
    Milbank Q; 2022 Jun; 100(2):562-588. PubMed ID: 35502786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specialty Drug Coverage Varies Across Commercial Health Plans In The US.
    Chambers JD; Kim DD; Pope EF; Graff JS; Wilkinson CL; Neumann PJ
    Health Aff (Millwood); 2018 Jul; 37(7):1041-1047. PubMed ID: 29985695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.